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Abstract 1 
 2 
In order to metastasise away from the primary tumour site and migrate into adjacent tissues, 3 
cancer cells will stimulate cellular motility through the regulation of their cytoskeletal 4 
structures. Through the coordinated polymerisation of actin filaments, these cells will control 5 
the geometry of distinct structures namely lamella, lamellipodia, filopodia and as well as the 6 
more recently characterised invadopodia. Because actin binding proteins play fundamental 7 
functions in regulating the dynamics of actin polymerisation, they have been at the forefront 8 
of cancer research. This review focuses on a subset of actin binding proteins involved in the 9 
regulation of these cellular structures and protrusions, and presents some general principles 10 
summarising how these proteins may remodel the structure of actin. The main body of this 11 
review aims to provide new insights into how the expression of these actin binding proteins is 12 
regulated during carcinogenesis and highlights new mechanisms that may be initiated by the 13 
metastatic cells to induce aberrant expression of such proteins.  14 
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1. Introduction 1 
Cellular migration is an essential feature of life which is responsible for numerous 2 
physiological processes including accurate embryogenesis and wound healing. In some cases, 3 
however, the pathways regulating cell motility can also be used for aberrant purposes such as 4 
the dissemination of tumour cells away from their primary site of growth. Whilst formation 5 
of neoplasms is by itself an important concern for human health, the steps that lead to 6 
invasion of other tissues by the primary tumour cells, a term referred to as metastasis, is much 7 
more life threatening. Indeed this dissemination of cells, resulting in the formation of 8 
secondary tumours in other organs, accounts for more than 90% of the fatalities associated 9 
with cancer progression. Although we have made remarkable steps toward understanding 10 
some aspects of the metastasis process, much still remains to be learned. Some of the key 11 
questions which will need to be addressed in the future should focus on understanding the 12 
cellular mechanisms that favour 1) the actual migration of cancer cells out of the primary 13 
tumour and 2) how they can successfully enter, survive and then leave the blood and 14 
lymphatic circulations (intravasation and extravasation, respectively) in order to generate 15 
secondary tumours in other specific tissues and organs of the body.  16 
In the majority of cases, the initial cellular events required to encourage metastasis are 17 
triggered by a switch from an epithelial cellular type to a less differentiated mesenchymal 18 
one, a process known as the epithelial mesenchymal transition (EMT) 1-3. During this 19 
transition, cells will sever links with neighbouring cells. The loss of expression of the E-20 
cadherin is seen as a hallmark towards such commitment4, 5. This down-regulation of E-21 
cadherin is regulated by specific transcriptional repressors such as those of the Snail family6, 22 
7. Another important step seen during carcinogenesis will result in changes in cellular 23 
migratory properties. Increased motility will encourage cells to move away from their initial 24 
niche and invade surrounding tissues. This migration can take place as a single cell 25 
(sometimes referred to as mesenchymal or amoeboid migration) or as a collective effort in 26 
cell sheets or clusters8. In both cases, the remodelling of the actin cytoskeleton is seen as a 27 
central step and significant alterations will take place at the cellular level. At the molecular 28 
levels, changes in the dynamics of actin polymerisation just under the plasma membrane will 29 
be the core process leading to these biological consequences. Pushing forces will be 30 
generated either directly or indirectly by the assembly of F-actin filaments and these forces 31 
will promote the formation of different protrusions at the leading edge, namely lamellipodia, 32 
filopodia, invadopodia and blebbing, all playing key roles in cellular migration, albeit under 33 
different circumstances9.  34 
Over the years, attention has been focused on identifying new cytoskeletal markers that 35 
demonstrate a good correlation between their expression and the degree of malignancy 36 
attained by tumour cells. Such candidate markers would have the potential to become 37 
invaluable tools to help comprehend better the stages involved in cancer biology, as well as 38 
providing powerful tools to improve both cancer prognosis and treatment.  Different actin 39 
binding proteins have come to the fore and have been the focus of recent comprehensive 40 
reviews10-12. The work presented here focuses only on a subset of known actin binding 41 
proteins, namely the Arp2/3 (Actin related protein 2 and 3 complex) and WASP/WAVE 42 
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(Wiskott-Aldrich Syndrome Protein / WASP and Verprolin homologous protein) complexes, 1 
fascin and the tropomyosins all involved at different levels in the regulation of 2 
lamellipodium, filopodium, lamellum and possibly blebbing, and whose expression is 3 
aberrantly regulated during carcinogenesis. This review analyses the recent developments in 4 
the field aiming to propose mechanisms that may be utilised by the metastatic cells in order to 5 
control abnormal expression of these actin binding proteins. These new regulatory 6 
mechanisms, if proven to be determinant in carcinogenesis, may translate into potential new 7 
avenues of research and treatment in the future. 8 
 9 
2. The actin cytoskeleton in tumour cell migration 10 
 11 
The process of cellular migration is engineered as a cyclic procedure composed of 1) 12 
extension of cellular leading edge in the forms of membrane sheet-like, finger-like or bleb-13 
like protrusion resulting from actin polymerisation in close proximity to the plasma 14 
membrane; 2) development of cell-extracellular contact points which may or may not be 15 
regulated by integrins and; 3) generation of forces by the actomyosin network to drive the 16 
morphological and architectural reorganisation that promotes cell movement. This review 17 
will focus mainly on specific actin binding proteins that promote extension of the leading 18 
edge and their involvement during cancer progression and metastasis, since other reviews 19 
summarising the global mechanisms of cell motility have recently been published 9, 13, 14.  20 
Studies analysing the migratory behaviour of tumour cells have demonstrated the 21 
architectural organisation of different actin-rich structures and molecules within, depending 22 
on the environment in which they grow. For instance, an environment that promotes 23 
sufficient mechanical contacts and loosely organised extracellular matrix (ECM) will 24 
encourage an amoeboid-type migration where cells adopt a characteristic rounded shape. This 25 
style of migration, which relies on the continuous formation of dynamic cellular membrane 26 
protrusions, results in rapid locomotion and is typically seen in leukocyte cell lineages 15 but 27 
has also been observed in tumour cells16. Amoeboid motility does not require integrin nor 28 
other molecular interaction with the ECM17 but relies on a continuous physical interaction 29 
and friction with the environment 18. Furthermore, although cortical actin polymerisation 30 
plays a fundamental role in this type of 3 dimensional (3D) migration, providing a support to 31 
stabilise the newly formed bleb bulging forward 19, the filaments do not directly generate the 32 
protruding forces necessary to push the plasma membrane, as seen during mesenchymal 33 
motility. Equally important is the role of the Rho-ROCK signalling pathway that regulates the 34 
contractile cortical actomyosin network20. Indeed the generation of contraction forces by 35 
myosin II causes the membrane to delaminate from/or fracture the actin cortex resulting in 36 
the inflow of cytoplasm and increased pressure at the plasma membrane in the direction of 37 
movement, leading to the formation of membrane blebbing at the leading edge16, 21.  38 
Movements of actin and related binding proteins into the bleb, during the later stages of 39 
inflation or in the process of retraction result in the formation of a cage like structure22. As 40 
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the expansion of the bleb slows down, erzin appears to be one of the first proteins, studied so 1 
far, to be recruited, followed rapidly by actin22. The four actin binding proteins α-actinin, 2 
coronin, tropomyosin-4 and fimbrin are also observed to move rapidly into the newly form 3 
protrusion. In the final stage of the bleb retraction, recruitment of components of the 4 
contractility apparatus such as myosin regulatory light chain and tropomodulin occur, 5 
resulting in the assembly of discrete foci at the bleb rim22. Importantly, none of the factors 6 
known to promote actin nucleation, such as Arp2/3 or mDia have been observed in the newly 7 
formed bleb, highlighting some uncertainties as to how actin polymerisation is controlled and 8 
regulated.   9 
Mesenchymal motility, which is typically seen during fibroblast migration, result in cells 10 
presenting a more elongated spindle-like shape, and orchestrating the modelling of different 11 
cellular organelles. Growth on 2 dimensional (2D) structures encourages cells to promote 12 
planar filamentous actin (F-actin) arrays known as filopodia/microvilli or sheet-like 13 
organisation identified as lamellipodia (Figure 1). Both of these structures rely on the 14 
controlled growth of the F-actin at their barbed end, leading to elongation of the filaments in 15 
the direction of the cell membrane. The overall morphology and molecular composition of 16 
these organelles determine their cellular importance. Lamellipodia are seen as the main 17 
driving force for locomotion and result from the large agglomeration of short branched 18 
filaments at the leading edge. The still increasing number of actin binding partners involved 19 
coordinate the nucleation of actin filaments (formins, Arp2/3/WASP complexes), their 20 
severing and depolymerisation from the pointed end (gelsolin, ADF (Actin Depolymerisation 21 
Factor)-cofilin) and the control of capping of the F-actin filaments (VASP (VAsodilator 22 
Stimulated Phosphoprotein), capping proteins, Arp2/3 complex)  9, 10. Contractile forces 23 
generated by myosin II activity are also required for stable lamellipodia extension and 24 
organisation, acting at the back of the lamellipodium and facilitating both actin filament 25 
disassembly at this location 23 as well as generating sufficient tensions to encourage focal 26 
adhesion maturation and stabilisation through the interactions of contact points with the 27 
substratum. Filopodia, on the other hand, are believed to act as sensory and guidance 28 
organelles, probing the external environment for cues. Reflecting the idea of a “probing stick 29 
or antenna”, they are rod-like extensions made of 10-30 tight bundles of long actin 30 
filaments24. Both formins and fascin have been shown to be major contributors in actin 31 
polymerisation in filopodia whilst both cdc42 and other Rho GTPase proteins are important 32 
to initiate the formation of filopodia 12, 24.   33 
However in a thick 3D ECM, and therefore a more in vivo environment, mesenchymal 34 
migration is dependent upon some significant proteolytic digestion of the ECM 25, a 35 
characteristic seen when cells develop a ventral membrane protruding a highly dynamic 36 
actin-rich structure with ECM degradation activity. These structures are known as 37 
invadopodia. These protrusions can be observed on the lateral side of invading cells, as well 38 
as at the front and also at the base and branching sites of invading structures25, 26. In a high 39 
proportion of cases, it seems that formation of invadopodia is a prerequisite for cellular 40 
invasion and has been observed for numerous cancer cell lines that are capable of invading in 41 
vitro assay systems or in animal xenograft models 27. Although a clear case for the 42 
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importance of invadopodia in invasion in vivo is still ill defined, circumstantial evidence has 1 
highlighted the importance of invadopodia associated proteins in metastasis promotion 28. For 2 
instance, using a xenograft model and through knockdown of N-WASP (Neural-Wiskott-3 
Aldrich Syndrome Protein), Gligorijevic et al 29 were able to demonstrate that inhibiting 4 
formation of invadopodium in vitro correlated with a loss of invasion, intravasation and lung 5 
metastasis. Others have suggested that lamellipodia and invadopodia, two independent 6 
structures when studied in 2D conditions, may indeed merge into one invasive structure, 7 
located at the cellular leading edge and be capable of multiple rounds of protrusion and 8 
retraction, when cells are cultured in a 3D matrix and in conditions in vivo 30.  9 
The molecular mechanisms underlying the formation of the structures involved in 10 
mesenchymal migration are still being characterised, but common factors have now been 11 
demonstrated to be involved in both sets of protrusions. Actin polymerisation is driven by the 12 
Arp2/3 complex and its nucleation-promoting factor N-WASP or WASP have been shown to 13 
be essential components of both invadopodia and lamellipodia/filopodia31-33. Recently, the 14 
well characterised actin bundling factor fascin, which is known to play a key role in 15 
promoting the protrusion of filopodia, has also been characterised as an essential component 16 
of invadopodia formation34. Finally, the tropomyosin family of proteins is thought to play 17 
important parts in both the amoeboid and mesenchymal-type migrations having been 18 
observed in both blebbing protrusions22 and regulating lamellipodia and filopodia35, 19 
respectively. Each of these components will now be discussed, in terms of their biological 20 
functions towards actin polymerisation, reviewing also their aberrant expression during 21 
carcinogenesis and highlighting possible molecular mechanisms that the cancer cells will 22 
deploy to achieve such changes.  23 
a) Arp2/3 and WASP/WAVE family 24 
 25 
The Arp2/3 complex consisting of 7 subunits (proteins ARPC1-5 and Arp2 and Arp3) 26 
polymerizes new actin filaments from the sides of existing filaments, forming 70o side-27 
branched networks. Because of their similarity in structure to the monomeric actin molecules, 28 
it is thought that the Arp2 and Arp3 proteins cooperate to form an active dimer for nucleation 29 
of the newly branching filament36. At the molecular level, it is thought that all seven subunits 30 
of the Arp2/3 complex play key roles in the binding of the complex to the actin mother 31 
filaments, but only the Arp2 and Arp3 subunits contribute to the initiation of the new 32 
daughter filament37. Regulation of the activity of the Arp2/3 complex to bind actin filaments 33 
is controlled by cortactin, through its interaction with the Arp3 subunit 38 or the WASP 34 
superfamily of proteins. This large family which is still in the process of being characterised, 35 
is currently composed of the WASPs (WASP and N-WASP) and SCAR/WAVEs partners 36 
(Suppressor of Cyclic AMP Receptor mutation and WASP and Verprolin homologous 37 
protein), is defined by a conserved C-terminal VCA domain. This domain is crucial for 38 
binding to the Arp2/3 complex and to the globular form of actin (G-actin), thereby recruiting 39 
all components to encourage new nucleation37, 39. The VCA domain is seen as the main 40 
regulatory element of WASP binding to the Arp2/3 complex and is tightly controlled by 41 
intra-molecular interactions that mask it away and prevent its interaction with other binding 42 
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partners. This direct auto-inhibition is the main regulator of the Arp2/3 promoting activity 1 
and is therefore recognised by a plethora of pathways including Rho family GTPases, 2 
phosphoinositide lipids, Src Homology SH3 domain containing proteins, kinases and 3 
phosphatases40. The N-terminal element of WASP family proteins is also seen as an 4 
important regulator of the biochemical activities of the VCA domains and is thought to be 5 
responsible for cellular localisation, as well to control the association with ligands. 6 
Expressions of WASP and WAVE proteins and that of the Arp2/3 complex have been shown 7 
to be altered during oncogenesis41 and such aberrant regulation result in important changes in 8 
the overall architecture of the actin cytoskeleton, principally the lamellipodium.  9 
Another cellular protrusion in the form of finger-like sensory and exploratory extensions 10 
which push the plasma membrane outward is the filopodia. This structure is primarily 11 
composed of parallel bundles of actin filaments (Figure 1). Their formation is regulated by a 12 
growing number of proteins including the Arp2/3 complexes 42.  Whilst it was originally 13 
perceived that the Arp2/3 complex was not required for filopodia formation, because of the 14 
absence of such branched structures in the thin finger-like structure, new experiments suggest 15 
that the complex may have important roles in the initiation of such protrusions since 16 
individual filaments of the filopodium emanate from the branching point on other filaments 17 
found in the lamellipodium43, 44. The actin bundling protein fascin has unequivocally been 18 
demonstrated to be a key regulator of filopodia stability.  19 
b) Fascin 20 
The 55-kD monomeric globular protein fascin has been shown to cross-links actin filaments 21 
in vitro into unipolar and tightly packed bundles 45 through 2 actin binding sites, located at 22 
the N- and C-terminal ends of the protein in what is thought to be 2 different β-trefoil 23 
domains 46, 47. Humans express three forms of fascins, fascin-1 and fascin-2 showing the 24 
highest degree of homology, whereas fascin-3 has only a very low homology with the other 25 
two isoforms48. Fascin-1 (termed from now on as fascin) is found ubiquitously expressed by 26 
mesenchymal tissues and in the nervous system, whereas fascin-2 and fascin-3 are much 27 
more precisely expressed in retinal photoreceptors and in testis, respectively 49.  The role of 28 
fascin in the formation of filopodia has been a rapidly expanding field and has generated 29 
wide-ranging interests due to its involvement in cancer progression (see below). Recent 30 
investigations have shed new light onto the mechanism for its regulation. The Rac and Rho 31 
proteins have been shown to act upstream of fascin through the PAK1 pathway or the p-Lin-32 
11/Isl-1/Mec-3 kinases,  respectively 50, 51, but the main body of work highlighting post-33 
translational modification of fascin activities has been demonstrated through the regulation of 34 
Protein Kinase C (PKC). Specific phosphorylation of serine 39 within the N-terminal actin-35 
binding domain by this kinase results in the loss of actin bundling by fascin52, 53, offering a 36 
possible mechanism to control fascin involvement in both physiological and disease states. 37 
The spatial localisation of fascin at the leading edge of crawling cells is important for the 38 
assembly of filopodia and the actin bundles generated through its bundling action allow the 39 
binding of the myosin motors II and V54.  Recent work suggests that F-actin filaments 40 
bundled by fascin may be important for the regulation of Myosin X motor processivity in 41 
filopodia formation 55.  42 
8 
 
Whilst both the Arp2/3 complex, its regulator and fascin play essential functions in the 1 
control of actin polymerisation and organisation, resulting in leading edge extension at the 2 
front of a migratory cell, other similarly important mechanisms are also required to promote 3 
cellular motility. Thus F-actin filaments need to be anchored to the extracellular environment 4 
via the formation of focal complexes and adhesions 13 and this change along with the 5 
remodelling of the actomyosin network generates tensile forces. It is the generation of such 6 
tensile forces by the myosin family of proteins that drives some of the morphological and 7 
architectural reorganisations that promote cell movement. The actomyosin contractile 8 
network represents a structural complex which is spatially posterior to the lamellipodium56 9 
and is referred to as the lamellum. The biological mechanisms responsible for the segregation 10 
of these two cellular subdomains are not clearly understood. The tropomyosin family of 11 
proteins may be one of the factors responsible for such spatial discrimination since they 12 
regulate the recruitment of myosin motors to the actin filaments57.  13 
 14 
c) Tropomyosin 15 
The tropomyosins (tpms) are thought to be mainly absent from the dynamic Arp2/3 16 
containing compartment58, although such concepts have been recently challenged following 17 
the observations of tropomyosin isoforms in both the lamellipodia and filopodia of spreading 18 
normal and transformed cells35. Originating from four distinct genes, there are today more 19 
than 40 tpms isoforms that have been discovered so far. More than 10 of these tpms isoforms 20 
are expressed from TPM1(a-TM) and TPM2 (b-TM) genes alone in vertebrate and are 21 
classified further into high molecular (HMW) and low molecular weights (LMW) tpms. 22 
Tpms are rod-shaped coiled-coil dimers actin-binding proteins that bind along the length of 23 
the actin filaments and have been implicated in the assembly and stabilisation of actin 24 
filaments59. Some recent advances in the field indicate that the isoforms Tm1, Tm2/3, and 25 
Tm5NM1/2 are required for assembly of stress fibres in cultured osteosarcoma cells, 26 
stabilising the actin filaments at distinct regions60. Tpms have also been shown to prevent 27 
ADF-cofilin or gelsolin interaction with F-actin in vitro, regulating also their localisation in 28 
the process, although such properties seem to be isoform-specific61, 62.  For instance, the 29 
tropomyosin isoform Tm5NM1 promotes inactivation of ADF-cofilin and leads to its 30 
displacement from the cell periphery while another isoform, TmBr3 stimulates the 31 
association of ADF-cofilin with actin filaments, therefore promoting its localisation at the 32 
leading edge63.  Interestingly, such properties also reflect the ability of these tropomyosin 33 
isoforms to recruit myosin II motors to the actin filaments with Tm5NM1 having a positive 34 
control over the binding of myosin II to F-actin filament whereas TmBr3 regulates its 35 
inactivity63. These diverse regulatory functions correlate with differential changes in cell size 36 
and shape, along with alterations in lamellipodial formation, increased cellular migration, and 37 
reduced stress fibers63.  38 
 39 
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All in all, the cellular pathways promoting cellular motility are diverse and complex and, not 1 
surprisingly, we find that the paths to carcinogenesis are similarly varied and multiple, 2 
involving the aberrant expression of many different targets. In an effort to correlate protein 3 
expression to possible mechanisms involved in their regulation, and the biological 4 
consequences of their interactions in cellular migration, this reviews brings together some of 5 
the recent findings that have shed new light on such processes, tackling in the first instance 6 
how the levels of these specific actin binding proteins are changes in the cancer cell (Table 7 
1).  8 
 9 
 10 
3. Regulation of specific actin binding proteins in cancer progression 11 
 12 
a) Arp2/3 and WASP/WAVE family 13 
 14 
The proteins of the Arp2/3 complex play essential orchestrating functions in actin 15 
organisation. Their binding to already formed actin filaments, forming 70o side-branched 16 
networks, is crucial for the modelling of the lamellipodia. Reports have shown that the 17 
metastasis process correlates with changes in the expression pattern of components of the 18 
Arp2/3 complex, although some uncertainty remains as to the degree of correlation as 19 
discussed below.  20 
Cancer progression of gastric cells appears to result in the robust and synchronous reduction 21 
in the expression of Arp2/3 proteins, with the reduction of at least four mRNAs of the seven 22 
subunits in more than 78% of the cases64. Among all components analysed, the Arp2, ARPC2 23 
and ARPC3 mRNAs, as determined by reverse transcriptase polymerase chain reaction, were 24 
found to be the most prominently reduced in cancer samples compared to their control 25 
counterparts. However, some of the gastric cancer cells and tissues had been obtained from 26 
primary tumours and no information was provided regarding their metastatic abilities. 27 
Furthermore, the experiments measured only the mRNA contents for the different 28 
components of the complex without assessing how the correlating protein levels were 29 
affected. More recent work investigating the aberrant levels of Arp2/3 proteins in pancreatic, 30 
colorectal and breasts carcinomas highlighted the elevation of the complex’s proteins with the 31 
rise in invasiveness and metastatic abilities.  Increased levels of both Arp2 and Arp3 proteins, 32 
measured by immunohistochemical staining correlated with the rise in atypical properties of 33 
the colorectal neoplasms65. This aberrant change in expression is not exclusive to the Arp2/3 34 
proteins as other components of the complex have also been shown to be affected during 35 
carcinogenesis. Expression pattern of the ARPC2 subunit has been reported to be increased in 36 
breast cancer cell lines66. The latter study provides further support for the role of ARPC2 as a 37 
sole promoter of cellular invasion, since knockdown of its expression using siRNA was 38 
sufficient to attenuate SK-BR3 breast cancer cells incursion into Matrigel. Independently 39 
other components of the Arp2/3 complex have been shown to be equally important in the 40 
pathogenesis of the head and neck squamous cell carcinoma, when the expression of the 41 
ARPC5 subunit at both the mRNA level and protein level were significantly up-regulated in 42 
malignant invasive cells and tissues compared to the control counterparts67. These 43 
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observations were further substantiated using human head and neck squamous cell carcinoma 1 
lines, that showed that high levels of ARPC5 expression resulted in both higher rates of 2 
cellular migration, cellular invasion, and to a certain extent cellular proliferation. When 3 
ARPC5 levels were specifically down-regulated in these cells, using siRNA, all these 4 
properties were significantly diminished when compared to the mock transfected control 5 
cells. Both results demonstrated the direct influence of ARPC5 on these pathways. 6 
It is unclear why such contradictory patterns of expression have been observed between the 7 
different studies. Studies using immunohistochemical analysis as only way to assess the 8 
levels of proteins may themselves have short-coming, as they do not offer a satisfying 9 
quantitative measurements of the real concentration and can further be influenced by the 10 
localisation of the proteins. Furthermore, besides the potential explanation that the different 11 
results are related to the different origins of the samples and tissues, there is also the more 12 
pertinent possibility that levels of the Arp2/3 proteins may be up-regulated at a specific time 13 
and/or indeed be critically required for the enhancement of invasive properties. Direct 14 
demonstrations using knockdown experiments above highlighted the importance of the 15 
expression of both ARPC5 and ARPC2 in enhancement of both cellular migration and 16 
invasion. It is therefore reasonable to suggest that invasive cells could gain an important 17 
selective advantage by aberrantly and timely up-regulating the expression of such proteins, 18 
whilst other tumour cells which fail to modulate such control will remain in their original 19 
environment.  20 
This suggestion is further supported by studies that aim to link directly the Arp2/3 complex 21 
and cell invasiveness. The subunits ARPC3 and ARPC5 have been shown to be expressed at 22 
high levels in the expression profiling of invasive subpopulations of MTLn3-derived or 23 
Polyoma Middle T oncogene (PyMT)–derived mammary tumor cells selected in vivo68, 69. In 24 
both instances, cells that demonstrated an ability to invade into adjacent tissues had up-25 
regulated the expression of the Arp2/3 complex components as well as molecules such as 26 
cofillin, to coordinate the activation of motility pathways.   27 
Moreover some degree of correlation has now been reported between the increased 28 
expression of Arp2 proteins, Arp3 proteins , cortactin and fascin and the tumour depth of 29 
invasion in gastric carcinoma70, or between components of the Arp2/3 complex and their 30 
activators, when significant up-regulation of WAVE2 and Arp2 are reported in breast cancer 31 
samples71, 72 and in colorectal carcinomas 73. Altogether, it is therefore tempting to speculate 32 
that although the expression of single components of the Arp2/3 complex may play an 33 
important role to promote cell migration away from the primary tumour, they may not in their 34 
own right be sufficient, and that concomitantly other actin binding proteins may also need to 35 
be specifically targeted.  36 
The importance of WASP and WAVE in the regulation of cancer invasion has been the topic 37 
of excellent recent reviews12, 41, 74 and will only be briefly discussed here. WASP/WAVE 38 
family of proteins play key functions in the regulation of the activity of the Arp2/3 complex, 39 
acting via the VCA region, to act as a scaffold to promote interactions between the complex 40 
and actin37. As a result, they are necessary for the cell protrusive activity that is associated 41 
with cell migration and invasion. Whilst WASP proteins have been shown to be directly 42 
responsible for the formation of invadopodium in carcinoma cells29, WAVE components 43 
appear to regulate formation of lamellipodia and membrane ruffles as well as that of 44 
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filopodia75-77. Reports have highlighted their possible implication with metastasis, as their 1 
expression encourages cells to migrate away from primary tumours. Thus recent work has 2 
shown that N-WASP activity is required for invadopodia in vivo and promotes some of the 3 
initial invasive steps of metastasis29. Not surprisingly protein levels of N-WASP have been 4 
shown to be increased in esophageal squamous cell carcinoma. This increase has been 5 
correlated with lymph node metastasis and pathological staging78. Similarly, WAVE proteins 6 
have also been found to be elevated in different cancer tissues. Thus a correlation between 7 
elevated levels of WAVE3 and advances in breast cancer progression has been highlighted79. 8 
Furthermore when WAVE3 is down-regulated using siRNA in MDAMB231 cells, the 9 
resultant cells show an inhibition in cell motility and invasion, suggesting that WAVE3 may 10 
be a significant element in tumour cell migration80. Similar observations were made 11 
following immunohistochemical staining for WAVE3 in prostate tumour sections or prostatic 12 
cancer PC-3 and DU-145 cell lines81. Once again, reducing WAVE3 to the more basal levels 13 
of non-tumorigenic cells led to a much reduced invasiveness, as quantified through cell 14 
penetration of the basement membrane, without affecting growth or matrix adhesion. In 15 
parallel WAVE2 transcription (mRNA and proteins) was reported to be at high levels in 16 
node-positive cases as well as in moderately and poorly differentiated breast tumours and it 17 
correlated with a poor prognosis82. 18 
The story is, however, not as clear cut as first thought, since more recent reports have now 19 
also indicated that low expressions of N-WASP or WAVE can also reflect a poor outcome. 20 
For instance N-WASP has been reported to act as a tumour suppressor gene both in vitro and 21 
in vivo using human breast cancer cell lines and tissues83. Both protein and mRNA levels, 22 
determined by immunohistochemical staining/Western blots analysis and quantitative PCR, 23 
respectively, on freshly collected breast tissues, revealed that cancer tissues presented much 24 
lower levels of expression of N-WASP than their control counterparts and that ectopic 25 
overexpression of N-WASP could significantly reduce motility and invasiveness of 26 
MDAMB231 cells in vitro, as well as reduced tumour growth in animals. However the ability 27 
of N-WASP overexpressing MDAMB231 cells to form secondary tumours and metastasis 28 
was never tested in this work, providing no further details as to the potential invasive 29 
properties of this protein. The same group reported that WAVE1 and WAVE3 transcripts 30 
were not increased in node-positive cases, as well as in moderately and poorly differentiated 31 
breast tumours82.   32 
b) Fascin 33 
Numerous reports link fascin to cancer progression. Importantly, fascin expression has now 34 
been reported to be associated with invasion of epithelial tumour cells and clinically 35 
aggressive tumours (see references herein and recent reviews48, 84). Fascin expression, 36 
revealed by immunohistochemical  staining, suggests that this protein is increased in 37 
dendritic cells and tumour epithelia in thymomas and thymic carcinomas 85, as well as in 38 
endometrioid carcinoma 86, pancreatic adenocarcinoma 87 and hepatocellular carcinoma 88. In 39 
the latter work, cortactin expression was also up-regulated along with that of fascin. The 40 
increased expression of fascin during cancer pathogenesis is not merely coincidental since 41 
when expression of fascin is induced using plasmid transfection in pancreatic tumour cells89 42 
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or oral squamous cell carcinoma90 motility and invasion of the transfected cells are increased. 1 
This up-regulation of fascin was mirrored by important increases in F-actin-based structures 2 
like filopodia and lamellipodia. The inverse experiment, where levels of fascin are down-3 
regulated, also provides evidences of it playing a key role in invasion. Thus when fascin 4 
levels are depleted in melanoma CHL1 cells or MDAMB231 breast adenocarcinoma cells by 5 
siRNA the resultant cells showed a reduction in invadopodia34. The mechanisms responsible 6 
for the promotion of invasion by fascin are still not fully understood but essential elements 7 
have recently been provided. It appears that the actin bundling properties of fascin are key for 8 
formation of invadopodia since expressing a form of the protein that has lost its actin 9 
bundling activities, following knockdown of the endogenous protein, failed to restore such 10 
migratory characteristics in CHL-1 or A375MM cells34.  11 
c) Tropomyosin 12 
Because of their important role in actin organisation and anchorage-independent growth, 13 
tropomyosins (tpms) have been classified as tumour suppressors 91.  Reduced levels of both 14 
tpm1 and tpm2 have been reported in tumorigenic cells thus highlighting their roles as core 15 
components of cell transformation92, 93.  More recent work also indicates that reduction or 16 
loss of tropomyosin correlate with tumours that invade and/or metastasise in breast, prostate, 17 
bladder and colon cancer, possibly through its regulatory function on the assembly of stress 18 
fibers94-96. Thus for example a marked reduction in tpm1 was found in metastatic breast 19 
MDAMB231 and colon SW620 cancer cell lines96. Moreover when tpm 1 was overexpressed 20 
in MDAMB231 cells, the level of stress fibers formation was increased and this correlated 21 
with a reduction in actin ruffles at the leading edges and a loss of cell motility96.  Similarly, 22 
Tm5NM1, a low molecular weight isoform from the TPM3 gene, inhibits both the 23 
mesenchymal to amoeboid and amoeboid to mesenchymal cell transitions, as a result of 24 
stabilisation of actin filaments and inhibition of cell migration in a 2D culture system97.  25 
Logically when Tm5NM1 was reduced the resultant cells were seen to increase significantly 26 
directional persistence, presumably through a greater formation of focal complexes98. From 27 
this information, it is probable that progression to metastasis by certain primary tumours may 28 
require the down-regulation of specific tpms but reports providing such information are, to 29 
the best of my knowledge, not currently available. In fact most of the information linking 30 
tropomyosins proteins to carcinogenesis presents them as potential promoters of cellular 31 
invasions. Thus tpm3 has been shown to be highly expressed in malignant breast tumour cells 32 
found in lymph nodes99. Furthermore, chromosomal translocation of the tpm3 gene to other 33 
DNA regions has also been reported to lead to carcinogenesis. Thus examples of the fusion of 34 
the tpm3 gene to the anaplastic lymphoma kinase ALK gene, resulting in the chimera TPM3-35 
ALK has been linked to inflammatory myofibroblastic tumours 100 and anaplastic large cell 36 
lymphoma101, whereas fusion of the tpm3 gene to the TRK kinase gene leads to human 37 
thyroid papillary carcinoma102. In all these cases, a direct role for tpm3 as an oncogene has 38 
always been in question since it could potentially act indirectly by promoting dimerisation/ 39 
multimerisation which would be sufficient to lead to activation of the associated kinase 40 
protein. A recent report however, demonstrates the presence of elevated levels of both tpm3 41 
mRNA and protein in human hepatocellular carcinoma when compared to the adjacent non-42 
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tumour liver tissue103. A significant correlation was also seen between elevated tpm3 levels 1 
and poor recurrence-free survival 103. Much remains to be learned about the role of tpm3 2 
during tumorigenesis, since it is currently unclear if tpm3 is solely responsible for all of the 3 
observations reported or happens to be a coincidental partner expressed during cancer 4 
progression.  5 
All in all, the roles of the different actin binding proteins listed here in carcinogenesis have 6 
been studied for many years, but uncertainties remain as to how they are involved and their 7 
biological consequences. The challenge now is to comprehend, at the cellular level, how 8 
different mechanisms may be diverted towards a single goal. Thus studies that concentrated 9 
on the expression of a solitary protein may therefore have been blinded from others changes 10 
that had taken place. A more globalistic approach, that has been embraced over the last few 11 
years to monitor changes in cancer cell progression, will in turn provide a much greater 12 
understanding of the different regulatory events responsible for the occurrence of metastasis. 13 
The ramifications of such comprehension may lead us to identify overlapping regulatory 14 
pathways that may be affected by cancer cells to alter the expression of specific proteins. 15 
 16 
4. Possible mechanisms high-jacked by cancer cells to regulate the expression of 17 
actin binding proteins 18 
A plethora of work has now highlighted the differential expression of actin binding proteins 19 
during carcinogenesis and acquirement of the metastatic state. It is, however, unclear as to 20 
how these protein levels are controlled both in terms of their global cytoplasmic expression 21 
and specific subcellular localisation. Indeed comparative genomic versus proteomic studies 22 
have indicated that mRNA expression is not always a good predictor of the changes in 23 
protein levels in eukaryotes104. Therefore different mechanisms acting post-transcriptionally 24 
may have been established to control gene expression and to regulate the levels of cellular 25 
proteins and these will be discussed in regards to the specific actin binding proteins that have 26 
been linked to cancer progression.  27 
MicroRNAs (miRNAs or miR) are a class of naturally occurring small (20-25 nucleotides) 28 
non-coding RNA molecules that have been shown to have critical roles in the regulation of 29 
gene expression, resulting in important control of biological and metabolic processes such as 30 
cell growth, differentiation, cell maintenance and cancer105, 106. The precursor miRNAs are 31 
initially transcribed by RNA polymerase II and further processed by RNAse III Dorsha and 32 
DGCR8. They are then exported by exportin 5 to the cytoplasm, where they will be converted 33 
into an active form by Dicer. Their post-transcriptional functions are exerted through the 34 
complementary binding of 3’-UTR (untranslated region) of target mRNAs, resulting in either 35 
their degradations or their blocks in translation107. Numerous lines of evidences indicate that 36 
miRNAs also play vital functions in tumorigenesis and their expressions is aberrantly 37 
regulated in several types of human cancers106.  Certain miRNAs such as miR-373 and miR-38 
520c have been classified as metastasis-promoting factors108, 109 while others play a role in 39 
inhibiting tumour invasion and metastasis. Indeed numerous studies have reported that miR-40 
145, miR-143 and miR-133a/b play a tumour-suppressive role in various cancers and are 41 
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consequently down-regulated in the miRNA expression signatures of various human 1 
malignancies 110-112113, 114. Their regulation has highlighted their importance in controlling 2 
specifically the levels of different actin binding proteins and hence they are discussed here 3 
(Table 2). 4 
a) Arp2/3 and WASP/WAVE family 5 
 6 
Studies of the Arp2/3 complex and its binding partners have significantly improved our 7 
understanding of the mechanisms that are in place in cells to modulate their actin 8 
polymerisation activities. Work presented so far in this review, also reveals that protein levels 9 
of the Arp2/3 complex are seen to be elevated during tumorigenesis in the great majority of 10 
cancers studied, but much remains to be discovered to explain how such increases are 11 
attained. A few new perspectives have now been put forward.  Using head and neck 12 
squamous cell carcinoma cells and a genome wide gene expression analysis, Kinoshita et al. 13 
have now demonstrated that mRNA for the subunit ARPC5 is a target for miR-133a 67. 14 
Whilst ARPC5 is seen as a marker of invasion and is significantly overexpressed in head and 15 
neck squamous cell carcinoma, silencing its expression by siRNA led to reduced migration 16 
and invasiveness. Interestingly, enhanced expression of miR-133a specifically down-17 
regulated levels of ARPC5 and also reverted the invasion and motility of the cells to a more 18 
wild type phenotype. Recent data has revealed that miR-133a functions as a tumour 19 
suppressor and its down-regulation plays a critical part during the progression of different 20 
tumours of the bladder or esophageal squamous cell carcinoma115. It is therefore tempting to 21 
speculate that such increase in tumorigenesis may in fact be linked to the enhanced 22 
expression of ARPC5 thereby causing an increase in invasiveness.  23 
Other miRNAs have also been reported to down-regulate specifically the expression of other 24 
subunits of the Arp2/3 complex, albeit not in tumour cells. ARPC3 has been identified as a 25 
target for miR-29a and miR-29b in primary hippocampal neurons and mouse N2A cells116, 26 
whereas miR-129-3p specifically reduces the level of Arp2 in human retinal pigment 27 
epithelial cells117. Although there is currently no information linking miR-29a and miR-29b 28 
in the progression of cancer, levels of miR-129-3p are affected by DNA hypermethylation in 29 
primary gastric cancers, resulting in reduced expression and correlating to poor clinic-30 
pathological features118. Direct connections have yet to be made between expression of miR-31 
129-3p and Arp2 levels in cancer cells and tissues, but these connections highlight another 32 
possible regulatory mechanism that cells could initiate en route to full carcinogenesis. More 33 
work in this field is therefore required to establish new links between these observations and 34 
the importance of Arp2/3 in metastasis. 35 
One needs to be mindful that posttranscriptional regulation of the expression of certain 36 
subunits of the Arp2/3 complex is not necessarily the only method to achieve such elevated 37 
levels. Other mechanisms are also being put forward to explain this phenomenon. Possible 38 
mechanisms for the overexpression of subunits of the Arp2/3 complex may also be linked to 39 
amplification of specific DNA target genes. Indeed, fluorescent in situ hybridisation of 40 
pancreatic cancer cell lines and primary tumours has revealed an increase in copy number of 41 
an amplicon core region containing the ARPC1A gene, this demonstrates a significant 42 
correlation between amplification and elevated levels of expression of ARPC1A119.  43 
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Although much remains to be discovered regarding the regulatory mechanisms that govern 1 
the expression of the family of WASP proteins in tumorigenesis, some recent findings are 2 
starting to shed light on this process. As we have seen, correlation between expression levels 3 
of WAVE3 and breast cancer progression have been highlighted, indicating that this protein 4 
may act as a key inducer of metastasis. A link between its expression and that of specific 5 
miRNAs, miR-31 and miR-200 have now also been recently documented120, 121. Thus an 6 
inverse correlation between expression of WAVE3 and that of either miR-31a or miR-200 7 
has been reported with WAVE3 levels increasing as cells underwent EMT while both miR-31 8 
and miR-200 levels were found to be reduced. These observations were seen to be more than 9 
mere coincidence since miR-31 and miR-200 were shown to target specifically a portion of 10 
the 3’-UTR of WAVE3 mRNA, and this resulted in a significant reduction of both its mRNA 11 
and protein, whereas its targeting had no effect on either WAVE1 or WAVE2 mRNAs. This 12 
initial descriptive observation will need to be characterised further to identify whether such 13 
regulation helps to trigger the progression of a tumour in to a more malignant state. 14 
 15 
b) Fascin 16 
As previously discussed, clear evidence has now demonstrated that elevated level of fascin is 17 
associated with poor prognosis and corresponds to changes in various tumours to more 18 
aggressive phenotypes (Table 1). Interestingly, increases in expression may be tightly linked 19 
to the process of metastasis, at least in human colon carcinomas, since levels of fascin appear 20 
to return to more basal levels once cells reach their destination where migration ceases and 21 
proliferation is enhanced122. Recent work has therefore been aimed at understanding how the 22 
elevated expression of fascin is regulated in such a precise and clockwork-like manner when 23 
it is required most, since experiments have shown that enhanced expression of fascin is solely 24 
capable of inducing cellular migration in vitro using colonic non-invasive carcinoma lines123. 25 
The regulatory mechanisms that could explain such observation are still currently lacking, 26 
although activation of pathways involving Insulin Growth Factor -1 (IGF-1) or Tumour 27 
Necrosis Factor alpha (TNF-α) have been shown to up-regulate specifically the expression of 28 
fascin in breast and bile duct carcinomas 124, 125, however the direct mechanisms need to be 29 
identified in greater depths. Alternatively recent reports over the last few years have 30 
established a link between fascin expression and that of specific miRNAs, mainly miR-31 
133a/b, miR-143 and miR-145 in prostate, bladder, esophageal squamous and in breast 32 
cancer cells 111-113, 126, 127.  Interestingly, most of these miRNAs have also now been shown to 33 
be specifically regulated in carcinogenesis110-113114 (see earlier comments). Indeed the miR-34 
145 cluster is located in 5q33, a region of the genome that has been shown to be frequently 35 
altered in cancers cells through chromosomal deletions, epigenetic changes and aberrant 36 
transcription. Experiments using the breast cancer cell line MDAMB231have further directly 37 
implicated the role of miR-145, since overexpression of miR-145 was shown to reduce 38 
dramatically the levels of fascin protein and coincidentally led to much reduced cellular 39 
invasion capabilities128. The inverse experiment also demonstrated that when miR-145 levels 40 
were lowered, using specific anti miR-145 oligonucleotides, invasive abilities were enhanced 41 
in less invasive breast tumour T47D cell lines128. These properties of miR-145 do not appear 42 
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to be breast specific since similar work link it to fascin expression and invasion in the DU145 1 
or PC3 prostate cancer cell models111 or bladder cancer cell lines113. The list of newly 2 
characterised miRNAs that can specifically target fascin is likely to rise in the future as recent 3 
reports demonstrate that miR-143 and miR-133a can similarly reduce its levels 113, 126. It 4 
remains to be elucidated however how exactly this process occurs and the biological 5 
relevance of such observations. For example is this suppressive effect directly due to the 6 
reduction in stability of fascin mRNA 111-113 or linked to the translation regulatory 7 
mechanisms that prevent the recruitments of its mRNA to the ribosomes? 8 
c) Tropomyosins 9 
Recently, independent experiments aiming to identify new target genes for miR-145, using 10 
comprehensive gene expression analysis, have implicated miR-145 as a regulator of tpm3 11 
levels, down regulating its expression in esophageal squamous cancer cells and prostate 12 
cancer cells111, 112. Similarly, tpm3 (as well as tpm2) were identified as target genes 13 
controlled by miR-133a in head and neck squamous cell carcinoma67. In all these cases 14 
however, such observations were not the direct focus of the investigations. Because these 15 
miRNAs are known tumour suppressors, down-regulation of the tpm 3 isoforms could 16 
possibly be a mechanism of such suppression. Establishing the true oncogenic nature of tpm3 17 
and whether a direct connection occurs between its expression and that of specific miR-133a 18 
and miR-145 should certainly provide a focus of future work.  19 
The link between miRNAs and tropomyosins also appears to involve other members of their 20 
respective families. Indeed gene repressing regulatory functions for miR-21 have also been 21 
shown towards tmp1 in MCF-7 and MDAMB231 cells129, 130. These breast cancer cell lines 22 
express high levels of miR-21 and coincidentally low levels of tpm1, one of the potential 23 
factors that could explain some of their malignant properties. When levels of miR-21were 24 
reduced in both of these cell lines they expressed high levels of tpm1, and sole expression of 25 
myc-tagged tpm1, by transfection of an expression vector, in the MDAMB231 cells was 26 
sufficient to reduce invasive capacity129. Interestingly, such regulations of tpm1 levels was  27 
shown to be exerted at the translational level, presumably through inhibition of the 28 
recruitments of tpm1mRNA to the ribosomes since its mRNA levels were unchanged130.  29 
Links have therefore now been initiated between tropomyosin isoforms and their regulation 30 
post-transcriptionally through specific miRNAs. This avenue of research is in its infancy, 31 
since such observations are currently mainly coincidental but they may prove to be 32 
biologically relevant and possibly key in the route to metastasis. 33 
 34 
d) Regulation of expression of specific actin binding proteins through localisation of 35 
their mRNAs at the leading edges of migratory cells 36 
Work in different organisms has now clearly demonstrated the importance of mRNA 37 
localisation of target proteins to the protein’s sites of function and their translation in situ. 38 
Thus localisation of β-Actin mRNA near the cellular leading edge promotes cell motility131 39 
since its delocalisation leads to a random distribution of the protein, as well as casual spatial 40 
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arrangement of the barbed end filaments and their nucleation sites132. Recent work has also 1 
indicated that localising actin mRNA at the leading edge is not a sole requirement since 2 
mRNAs encoding core components of both the lamellipodium and focal adhesions may also 3 
be selectively targeted to this region. Indeed, through the use of both fluorescent in situ 4 
hybridisation and tyramide-signal amplification, mRNAs for the seven members of the 5 
Arp2/3 complex were found to be localised to protrusions in fibroblast cells133. As for the 6 
displacement of the β-actin mRNAs to non-physiological subcellular regions, recent work has 7 
shown that preventing the proper localisation of the Arp2 mRNA to the leading edge leads to 8 
narrow cellular protrusions and loss of directionality134.  9 
Similarly localisation of α-actinin mRNAs to the leading edge has been shown to be critical 10 
for the proper regulation of the assembly of focal adhesion sites and migration135. 11 
Experiments looking at mRNA localisation in highly invasive MDAMB231 cells have shown 12 
that α-actinin mRNA levels are remarkably low at the leading edge, presumably correlating 13 
with low amount of proteins, this low level results in small and largely un-matured focal 14 
adhesions 135. Moreover when the localisation of α-actinin mRNAs at actin-rich cellular 15 
protrusion was elevated, through the increased expression of the Zipcode Binding Protein 1 16 
(ZBP1, discussed further below), increased size and greater levels of mature focal adhesions 17 
were produced, suggesting a link between mRNA spatial organisation of α-actinin and 18 
assembly of focal adhesions.  19 
It is therefore conceivable that proteins whose function is to target specific mRNAs to precise 20 
regions in cells could therefore “indirectly” regulate the direct functions of such proteins. One 21 
such factor is ZBP1, a primarily cytoplasmic 68 kDa protein, which contains several 22 
recognizable regions, including two RNA-recognition motifs, four hnRNP K homology 23 
domains, as well as potential nuclear localization and export signals 136. ZBP1 binds to 24 
specific mRNAs through the recognition of cis-acting elements usually found in the 3’-25 
UTR136 (and reviewed in137). mRNAs for components of the Arp2/3 complex and α−actinin 26 
have been shown to bind to ZBP1 proteins in MTLn3 breast cancer cells in microarray 27 
experiments138.  High expression of ZBP1 results in the localisation of their mRNAs at the 28 
cell leading edge and as a result is directly implicated in decreased turnover of focal 29 
adhesions135. This in turn leads to loss of the metastatic potential of a cell line derived from 30 
breast tumours68. Conversely, when ZBP1 expression is repressed, this change not only 31 
increases cell migration, but also promotes the proliferation of metastatic cells138. 32 
Coincidentally, or possibly strikingly, it appears that the same cells that boost the levels of 33 
the Arp2/3 complex proteins are also the ones that reduce the amount of ZBP1 on their route 34 
to metastasis68, 69.  All together these reports indicate that the steps when ZBP1 is down-35 
regulated and the expression of specific actin binding proteins is simultaneously increased 36 
may be critical in metastatic progression. This step could control both structural regulation of 37 
the leading edge and cell polarity along with assembly of focal adhesions and their stability 38 
by spatially regulating the translation of both the mRNAs discussed as well as others 39 
potentially relevant to motility.  To support this theory, a significant decrease in transcription 40 
activity of the ZBP1 gene has been observed in cells from metastatic tissues through 41 
methylation of its promoter region. Such changes have resulted in a dramatically silenced 42 
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expression of ZBP1 in highly invasive cells (MTLn3 and MDAMB231) compared to non-1 
invasive cells138. The route to metastasis is a twisted, not necessarily unique path, that will be 2 
achieved through a series of regulatory events. It is therefore conceivable to speculate here 3 
that different mechanisms, working synergistically, will be at play to accomplish a common 4 
goal. Regulating the expression of specific actin binding proteins such as those of the Arp2/3 5 
complex, along with that of ZBP1 may be key for such progression and future work may 6 
focus on analysing their levels in cancerous tissues and samples.  7 
Whilst there is little doubt that transport of specific mRNAs to the leading edge will play 8 
essential roles in regulating the expression of factors involved in lamellipodia, filopodia and 9 
invadopodia, it is still uncertain as to how these targeted mRNAs will be retained at the 10 
correct subcellular site. Although the role of ZBP1 or other carrier is critical for the transport 11 
of the actin binding proteins, they do not by themselves interact directly with structures that 12 
would allow their accumulation and anchoring at specific sites. Although no factors have so 13 
far been reported for the mRNAs of either components of the Arp2/3 complex or α-actinin, 14 
β-actin mRNA has been shown to be anchored onto actin filament by the eukaryotic 15 
Elongation Factor 1 alpha (eEF1A) 139.  16 
eEF1A, whose primary function is the delivery of amino-acyl tRNAs to the elongating chain 17 
of the newly synthesised protein of the ribosome has also been reported to have numerous 18 
other non-canonical functions; one of these functions is the  remodelling  of the actin 19 
cytoskeleton which occurs throughout eukaryotes139-141. Both mammalian isoforms, eEF1A1 20 
and eEF1A2 have been reported to be important in carcinogenesis although not necessarily 21 
for the same reason142, 143. eEF1A2 has been shown to promote the formation of filopodia 22 
through the generation of phosphatidylinositol-4,5 biphosphate in both the cytosolic and 23 
membrane bound cellular compartments 144, a regulatory mechanism that appears to play an 24 
important role in acinar development and mammary neoplasia 145. A direct connection 25 
between tumorigenesis and eEF1A1 remains elusive, but could be linked to its ability to 26 
interact with the actin cytoskeleton142, through regulation of the Sphingosine kinase 1146 or 27 
intracellular alkalinization-induced tumour cell growth147. It appears, however, that increased 28 
expression of eEF1A can lead to transformed phenotypes148. More recently, the levels of 29 
expression of eEF1A1 and its role during cancer progression has led to further uncertainty. 30 
Some observations demonstrate increased eEF1A1 levels as single cells acquire metastatic 31 
properties in primary mammary tumours 149 but eEF1A1 levels were subsequently found to 32 
be significantly decreased in an invasive subpopulation of Polyoma Middle T oncogene 33 
(PyMT)-derived mammary tumours, to a level similar to that of ZBP169. Further work on the 34 
eEF1A protein is therefore required to shed more lights onto the potential oncogenic 35 
properties of this factor and whether its ability to spatially organise mRNAs for actin and for 36 
potential other target proteins that have  hitherto not yet been identified plays some role in the 37 
metastatic process. 38 
5. Concluding remarks 39 
The route to carcinogenesis is a lengthy and time-consuming process, as is the road that 40 
scientists have been following in order to make sense of it all. In a mass of tumour cells, 41 
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some cells will regulate concurrently the expression of many different proteins, this is a key 1 
step required to acquire more invasive properties, thereby allowing cells to infiltrate adjacent 2 
tissues. Indeed, the penetration of the basal membrane, and the surrounding structures of this 3 
physical barrier is seen as one of the most significant characteristics of malignancy. Yet it is 4 
also one of the most challenging aspects of the cancer pathology to recapitulate in vitro since 5 
cell invasion requires dynamic interaction between the tumour cells, especially when 6 
considering collective migration, host cells from neighbouring and distant tissues to be 7 
invaded and the basal membrane matrix itself. Recent advances, using elegant ex vivo or in 8 
vivo techniques, such as the rat peritoneal basal membrane 33 or chick chorioallantoic 9 
membrane 150 invasion assays, respectively, have generated new avenues of  research that 10 
will provide further insights in to the different steps of invasion and will allow identification 11 
of more of the important players in this process. A subset of actin binding proteins, some of 12 
which have been presented in this work, have now advanced as hallmarks for carcinogenesis 13 
and some possible mechanisms for their regulations have also been reviewed. More in depth 14 
studies on the importance of miRNAs and on localised regulation of protein expression will 15 
be needed to provide a more complete picture of the mechanisms that facilitate cellular 16 
invasion. In turn, the potentially newly-characterised factors involved in this process may 17 
prove to be targets that will allow us to understand their full potential in tumour progression. 18 
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Legend 1 
 2 
Figure 1: Actin organisation in migrating cancer cell 3 
A) Staining for F-actin using Phalloidin-Alexa488 in a migrating Rama 37 malignant cell 4 
expressing high levels of S100A4. In this image, the structures of lamellipodium/lamellum 5 
and filopodium are clearly visible at the leading edge of the cell. B and C present models for 6 
the lamellipodium/lamellum and filopodium and the respective molecular organisation 7 
within, focusing on the proteins presented in this review. B) A simplified model for 8 
lamellipodium/lamellum formation. In the lamellipodium, free barbed ends of actin filaments 9 
recruit the Arp2/3 complex via activation by WASP/WAVE complex and cortactin. The 10 
Arp2/3 complex nucleates a new actin filament from the side of existing filaments and 11 
remains at the branching point. In the lamellum, actin filaments are bound to tropomyosins, 12 
preventing interactions with other actin binding proteins. C) A simplified model for filopodia 13 
formation. Individual filaments of the filopodium emerge from the branching point on other 14 
filaments, through actin polymerisation promoted by the Arp2/3 complex. Further addition of 15 
actin monomers at the barbed end of actin filaments is nucleated by the formin family, 16 
whereas fascin regulates filopodia stability through its bundling activities. 17 
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List of abbreviations 7 
ADF   Actin depolymerising factor 8 
Arp2/3 complex  Actin related protein 2 and 3 complex 9 
ARPC   Actin related protein complex subunit 10 
ECM   Extracellular matrix 11 
eEF1A   Eukaryotic Elongation Factor 1 alpha 12 
EMT    epithelial mesenchymal transition  13 
F-actin   Filamentous actin 14 
G-actin  Globular actin 15 
HMW   High molecular weight 16 
LMW   Low molecular weights  17 
miRNA or miR MicroRNAs  18 
PKC   Protein kinase C 19 
siRNA   Small interference RNA 20 
Tpms    Tropomyosins  21 
UTR   Untranslated region 22 
VASP   Vasodilator stimulated phosphoprotein 23 
WASP   Wiskott-Aldrich Syndrome Protein 24 
WAVE  WASP and Verprolin homologous protein 25 
ZBP1   Zipcode Binding protein 1  26 
2D    Two dimensional 27 
3D   Three dimensional 28 
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Table 1: Regulations of actin binding proteins in cancer tissue samples and cell lines  
Actin binding protein 
affected 
Level of regulation and 
tumour origins 
References 
Arp2/3 
Arp2 
 
 
 
 
Arp3 
 
 
ARPC1 
 
ARPC2 
 
 
ARPC3 
 
 
 
ARPC5 
 
 
 
 
Down in gastric carcinoma 
Up in gastric carcinoma 
Up in colorectal carcinoma 
Up in breast carcinoma  
 
Up in colorectal neoplasms 
Up in gastric carcinoma 
 
Up in pancreatic carcinoma 
 
Down in gastric carcinoma 
Up in breast carcinoma 
 
Down in gastric carcinoma 
Up in breast cancer cell lines 
Up in PyMT tumor cells   
 
Up in breast cancer cell lines 
Up in PyMT tumor cells   
Up in head and neck 
squamous cell carcinoma 
 
64 
70 
65,73 
71,72 
 
65 
70 
 
119 
 
64 
66 
 
64 
68 
69 
 
68 
69 
67 
 
WASP/WAVE 
 
N-WASP 
 
 
 
WAVE1 
 
 
WAVE 2 
 
WAVE3 
 
 
 
 
 
Down in breast carcinoma 
Up in esophageal squamous 
cell carcinoma 
 
No changes in breast 
carcinoma 
 
Up in breast carcinoma 
 
No changes in breast 
carcinoma 
Up in breast carcinoma 
Up in prostate carcinoma  
 
 
83 
78 
 
 
82 
 
 
82 
 
82 
 
79 
81 
Fascin 
 
 
 
 
 
 
 
Up in thymomas and thymic 
carcinomas  
Up in endometrioid 
carcinoma,  
Up in pancreatic 
adenocarcinoma  
Up in hepatocellular 
carcinoma 
 
85 
 
86 
 
87 
 
88 
Tropomyosin 
 
Tpm1 
 
 
 
 
Tpm3 
 
 
 
ALK-TPM3 
 
 
 
 
TRK-TPM3 
 
 
Down in breast cancer cell 
line 
Down in colon cancer cell 
line 
 
Up in breast cancer 
Up in hepatocellular 
carcinoma 
 
Up in inflammatory 
myofibroblastic tumours 
Up in anaplastic large cell 
lymphoma  
 
Up in thyroid papillary 
carcinoma  
 
 
96 
 
96 
 
 
99 
103 
 
 
100 
 
101 
 
 
102 
 
 
Table 2: miRNAs dependant mechanisms regulating the levels of actin binding proteins in 
different cancer samples and cell lines    
Actin binding 
protein affected 
Possible miRNA 
mechanisms  
Tumour origin References 
Arp2/3 
ARPC5  
 
 
miR-133a  
 
 
 
Head and neck 
squamous cell 
carcinoma  
 
67 
 
 
WASP/WAVE 
 
WAVE3 
 
 
 
miR31  
 
 
 
 
 
 
miR-200 
 
 
Breast cancer cell 
lines 
Prostate cancer cell 
line 
 
Breast cancer cell 
line 
Prostate cancer cell 
lines 
 
 
121 
 
121 
 
 
120 
 
120 
Tropomyosin 
 
Tpm1 
 
 
 
Tpm2 
 
 
 
Tpm3 
 
 
 
miR-21 
 
 
 
miR-133a 
 
 
 
miR-133a 
 
 
 
miR-145 
 
 
 
Breast cancer cell 
lines 
 
Head and neck 
squamous cell 
carcinoma 
 
Head and neck 
squamous cell 
carcinoma 
 
Prostate cancer cell 
lines 
Esophageal 
squamous cancer 
carcinoma  
 
 
 
129,130  
 
 
67 
 
 
 
67 
 
 
 
111 
 
 
112 
Fascin 
 
 
 
miR-133a  
 
 
 
miR-143  
 
 
 
miR-145 
 
 
Bladder cancer cell 
lines 
 
Esophageal 
squamous cell 
carcinoma 
 
Breast cancer cell 
lines.  
Prostate cancer cell 
lines  
113 
 
 
126 
 
 
 
128 
 
111 
 
 
 
 
 
 
Bladder cancer cells 
lines 
Esophageal 
squamous cancer cell 
lines 
 
113 
 
 
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
